Windtree Therapeutics, Inc. announced that it is preparing for an interim analysis of its SEISMiC C Phase 2 study of istaroxime, targeting results for July 2025. This global, placebo-controlled, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results